BioCentury | Apr 27, 2018
Finance

Revolution revamp

...products. When the company launched in 2015, its lead candidate was an antifungal based on amphotericin B...
BioCentury | Feb 23, 2018
Financial News

Taiwan Liposome planning NASDAQ listing

...advanced breast cancer and cutaneous T cell lymphoma (CTCL); and Ampholipad, a liposomal formulation of amphotericin B...
BioCentury | Feb 20, 2018
Financial News

Taiwan Liposome planning NASDAQ listing

...advanced breast cancer and cutaneous T cell lymphoma (CTCL); and Ampholipad, a liposomal formulation of amphotericin B...
BioCentury | Jan 26, 2018
Company News

Taiwan Liposome forms JV with Jixi in China

...advanced breast cancer and cutaneous T cell lymphoma (CTCL) and Ampholipad, a liposomal formulation of amphotericin B...
BioCentury | Jan 23, 2018
Company News

Taiwan Liposome forms marketing JV with Jixi

...advanced breast cancer and cutaneous T cell lymphoma (CTCL) and Ampholipad, a liposomal formulation of amphotericin B...
BioCentury | Jan 19, 2018
Clinical News

Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis

...the open-label, U.S. trial include safety and pharmacokinetics. MAT2203 is a lipid-crystal nanoparticle formulation of amphotericin B...
...Bedminster, N.J. Product: MAT2203 (CAmB) Business: Infectious Molecular target: Ergosterol Description: Lipid-crystal nanoparticle formulation of amphotericin B...
BioCentury | Sep 9, 2017
Strategy

Some of the parts

...“Other products” includes Letairis ambrisentan for pulmonary arterial hypertension, Ranexa ranolazine for chronic angina, AmBisome amphotericin B...
BioCentury | Aug 24, 2017
Translation in Brief

The skinny on leishmaniasis

...of VL. There are two marketed therapies for VL: AmBisome amphotericin b, a unilamellar formulation of amphotericin B...
...other forms of the disease; and iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF) has ICo-009 , oral amphotericin B...
BioCentury | Aug 24, 2017
Translation in Brief

Spit it out

...infection while a second agent eliminates the pathogen. Standard of care for Cryptococcal disease is amphotericin B...
BioCentury | Jul 13, 2017
Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

...on its development plans for MAT2203 this quarter. MAT2203 is a lipid-crystal nanoparticle formulation of amphotericin B...
...Product: CAmB ( MAT2203 ) Business: Infectious Molecular target: Ergosterol Description: Lipid-crystal nanoparticle formulation of amphotericin B...
Items per page:
1 - 10 of 455